Potent immune responses against thermostable Foot-and-Mouth disease virus VP1 nanovaccine adjuvanted with polymeric thermostable scaffold

Vaccine. 2024 Feb 6;42(4):732-737. doi: 10.1016/j.vaccine.2023.12.079. Epub 2024 Jan 13.

Abstract

Foot-and-mouth disease (FMD) is an acute zoonosis causes significant economic losses. Vaccines able to stimulate efficient protective immune responses are urgently needed. In this study, Escherichia coli-derived recombinant VP1 of serotype A and O FMD virus (FMDV) was conjugated to thermostable scaffold lumazine synthase (LS) or Quasibacillus thermotolerans encapsulin (QtEnc) using a robust plug-and-display SpyTag/SpyCatcher system to generate multimeric nanovaccines. These nanovaccines induced highly potent antibody responses in vaccinated mice. On day 14 after the first immunisation, antibody titres were approximately 100 times higher than those of monomer antigens. Both vaccines induced high and long-term IgG antibody production. Moreover, the QtEnc-VP1 nanovaccine induced higher antibody titres than the LS-VP1 nanovaccine. The nanovaccines also induced Th1-biased immune responses and higher levels of neutralising antibodies. These data indicated that FMDV nanovaccines generated by conjugating VP1 with a thermostable scaffold are highly immunogenic and ideal candidates for FMDV control in low-resource areas.

Keywords: Foot-and-mouth disease virus (FMDV); Lumazine synthase; Nanovaccine; Quasibacillus thermotolerans encapsulin; Thermostability; VP1.

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Antibodies, Viral
  • Capsid Proteins
  • Foot-and-Mouth Disease Virus*
  • Foot-and-Mouth Disease*
  • Immunity
  • Mice
  • Nanovaccines
  • Viral Vaccines*

Substances

  • Nanovaccines
  • Antibodies, Viral
  • Viral Vaccines
  • Adjuvants, Immunologic
  • Capsid Proteins